ISSN 1674-3865  CN 21-1569/R
主管：国家卫生健康委员会
主办：中国医师协会
　　　辽宁省基础医学研究所
　　　辽宁中医药大学附属医院
中国中西医结合儿科学

中国中西医结合儿科学 ›› 2017, Vol. 9 ›› Issue (5): 430-432.doi: 10.3969/j.issn.1674-3865.2017.05.021

• 脓毒症专栏 • 上一篇    下一篇

孟鲁司特纳联合布地奈德治疗小儿咳嗽变异性哮喘疗效观察

张迎霞   

  1. 473500 河南 南阳，河南省新野县人民医院儿科
  • 出版日期:2017-10-25 发布日期:2017-12-18
  • 作者简介:张迎霞（1976-），女，主治医师。研究方向：小儿呼吸系统疾病的诊治，E-mail：ndfhislhgi@sina.com

Clinical effect of montelukast sodium and budesonide in children with cough-variant asthma

ZHANG Yingxia   

  1. Xinye People's Hospital of He'nan, Nanyang 473500,China
  • Online:2017-10-25 Published:2017-12-18

PDF (PC)

72

摘要：
目的
观察孟鲁司特纳联合布地奈德治疗小儿咳嗽变异性哮喘的临床疗效。
方法
选择2014年7月至2015年6月河南省新野县人民医院儿科收治咳嗽变异性哮喘患儿140例，随机分为观察组与对照组，每组各70例。对照组采用布地奈德进行雾化治疗，观察组在对照组治疗基础上给予孟鲁司特纳片口服。两组均治疗12 d。观察两组临床疗效及肺功能相关指标：1 s用力呼气容积(FEV1)、最大呼气流量(PEF)和FEV1/FVC比值。
结果
观察组总有效率为98.6%（69/70），显著高于对照组77.1%（54/70），差异有统计学意义（P<0.05）。治疗前，观察组与对照组肺功能指标FEV1、PEF和FEV1/FVC比较差异无统计学意义（P>0.05）|治疗后观察组FEV1、PEF和FEV1/FVC均显著高于对照组，差异有统计学意义（P<0.05）。
结论
采用孟鲁司特纳联合布地奈德治疗小儿咳嗽变异性哮喘，可有效提升治疗疗效，具有临床应用价值。

关键词: 咳嗽变异性哮喘, 孟鲁斯特纳, 布地奈德, 儿童

Abstract:
Objective
To study the clinical effect of montelukast sodium and budesonide in children with cough-variant asthma.
Methods
A total of 140 children with cough-variant asthma treated from July 2014 to June 2015 in our hospital were selected. The subjects were divided into two groups according to the different therapies, 70 cases in each group. Group B took budesonide; group A took the combined therapy of montelukast sodium and budesonide; the treatment lasted for 12 days. The clinical effect for two groups was analyzed, and observe the indexes related to pulmonary function:FEV1, PEF and FEV1/FVC.
Results
The total effective rate of the observation group was 98.6%(69/70), significantly higher than that of control group(77.1%,54/70), and there was statistical difference(P<0.05).Before treatment,there was no statistical difference in such pulmonary indexes as FEV1,PEF or FEV1/FVC between the observation and control group(P>0.05), but after treatment these indexes were significantly higher in the observation group than in the control group with statistical difference(P<0.05).
Conclusion
The combined therapy of montelukast sodium and budesonide can efficiently improve the clinical effect in the treatment of children with cough-variant asthma, which is worthy of clinical application.

Key words: Cough-variant asthma, Montelukast sodium, Budesonide, Children